HCM News and Press, HUTCHMED (China) Limited From 12/20/21

Hutchmed (NASDAQ:HCM) has been included by FTSE Russell in the FTSE Global Equity Index Series in its quarterly review, including the FTSE All-World, FTSE Global All Cap, FTSE Global Total Cap and FTSE Global Mid Cap Indexes. The inclusions come into effect on Monday, December 20, 2021. For...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 19, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has been included by FTSE Russell in the FTSE Global Equity Index Series (“GEIS”)...

Following a sharp decline on Wednesday amid concerns over an impending U.S. crackdown, Chinese biotech companies listed in the U.S. have rebounded sharply after the Department of Commerce published a list of sanctioned entities clarifying the earlier reports. Notable gainers include I-Mab (IM...

Chinese biotech companies listed on U.S. financial markets are trading lower in the pre-market amid reports that the Biden administration is weighing tougher sanctions on China’s largest chipmaker, Semiconductor Manufacturing International Corp. (OTCQX:SMICY). A meeting scheduled for T...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 14, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces new analyses on the ongoing studies of HMPL-523 presented at the 63 rd American Society for Hematol...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 10, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new analyses and updates on the ongoing studies of surufatinib combined with toripalimab, in multiple dis...

Hutchmed (China) (NASDAQ:HCM) has completed patient enrollment of FRESCO-2, a Phase III registration study of fruquintinib, an investigational treatment for the treatment of patients with metastatic colorectal cancer (CRC) in U.S., Europe, Japan and Australia. Shares up 4.5% premarket&#x...

— Recruitment of 687 patients globally completed in fifteen months, ahead of schedule — — FRESCO-2 primary objective is to confirm overall clinical benefit seen in the China FRESCO pivotal study 1 , and to support global registrati...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 03, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; HKEX:13) today announces that, following the 2021 negotiations with the China National Healthcare Security Administration (...

A newly detected coronavirus variant in Africa created panic and sparked a market selloff in the holiday-shortened week. However, the developers of COVID-19 vaccines and therapeutics advanced while several common stock offerings pressured decliners. Despite the outperformance of biotech stock...